A clinical-stage biotech engineering gene therapies for inherited blindness, dry mouth from radiation, and brain diseases like Parkinson's and ALS. Think of it as rewriting faulty genetic code to fix diseases at the source.
Money comes from a Janssen Pharmaceuticals collaboration, with a one-off USD 0.32B revenue spike in Q2 2026 (50% net margin). Core operations lose money annually—2025 revenue was USD 0.08B with a USD -0.11B net loss—so no recurring profit yet.
Proprietary riboswitch technology lets gene therapies be turned on/off, a unique switch competitors like Spark Therapeutics and Sarepta Therapeutics lack. But the moat is eroding as bigger players like Novartis and Pfizer pour billions into rival gene therapy
Key events, in time order
Earnings beat and FDA designation boost fundamentals
None yet
None yet
MeiraGTx Holdings plc is listed as a top trade for tomorrow, suggesting a potential short-term trading opportunity based on the user's watchlist strategy.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
